Association of genetic polymorphisms in the VEGF gene with breast cancer survival.
暂无分享,去创建一个
X. Shu | W. Zheng | Q. Cai | W. Wen | Z. Ruan | Yong Cui | N. Kataoka | Yu-Tang Gao | Hua Lu | Yu-Tang Gao | Yu-Tang Gao
[1] Kenneth J. Hillan,et al. Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer , 2004, Nature Reviews Drug Discovery.
[2] P. Brenchley,et al. Association of the VEGF gene with proliferative diabetic retinopathy but not proteinuria in diabetes. , 2004, Diabetes.
[3] C. N. Coleman,et al. Urinary VEGF and MMP levels as predictive markers of 1-year progression-free survival in cancer patients treated with radiation therapy: a longitudinal study of protein kinetics throughout tumor progression and therapy. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[4] X. Shu,et al. Genetic polymorphisms in the TGF-beta 1 gene and breast cancer survival: a report from the Shanghai Breast Cancer Study. , 2004, Cancer research.
[5] Peter Donnelly,et al. A comparison of bayesian methods for haplotype reconstruction from population genotype data. , 2003, American journal of human genetics.
[6] B. Paulweber,et al. A common 936 C/T gene polymorphism of vascular endothelial growth factor is associated with decreased breast cancer risk , 2003, International journal of cancer.
[7] F. Tsai,et al. Vascular endothelial growth factor gene-460 C/T polymorphism is a biomarker for prostate cancer. , 2003, Urology.
[8] N. Ferrara,et al. The biology of VEGF and its receptors , 2003, Nature Medicine.
[9] D. Ray,et al. Haplotype analysis of the polymorphic human vascular endothelial growth factor gene promoter. , 2003, Cancer research.
[10] Ikuo Inoue,et al. A common polymorphism in the 5'-untranslated region of the VEGF gene is associated with diabetic retinopathy in type 2 diabetes. , 2002, Diabetes.
[11] Peter H. Westfall,et al. Testing Association of Statistically Inferred Haplotypes with Discrete and Continuous Traits in Samples of Unrelated Individuals , 2002, Human Heredity.
[12] T. H. van der Kwast,et al. High tumor levels of vascular endothelial growth factor predict poor response to systemic therapy in advanced breast cancer. , 2001, Cancer research.
[13] S. Fan,et al. Clinical implications of circulating angiogenic factors in cancer patients. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[14] W. Renner,et al. A Common 936 C/T Mutation in the Gene for Vascular Endothelial Growth Factor Is Associated with Vascular Endothelial Growth Factor Plasma Levels , 2000, Journal of Vascular Research.
[15] P. Carmeliet,et al. Angiogenesis in cancer and other diseases , 2000, Nature.
[16] M. Bottomley,et al. Identification of polymorphisms within the vascular endothelial growth factor (VEGF) gene: correlation with variation in VEGF protein production. , 2000, Cytokine.
[17] T. Sellers,et al. Association of menstrual and reproductive factors with breast cancer risk: Results from the Shanghai breast cancer study , 2000, International journal of cancer.
[18] R. Henriksson,et al. Correlation of vascular endothelial growth factor content with recurrences, survival, and first relapse site in primary node-positive breast carcinoma after adjuvant treatment. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[19] O. Vinante,et al. Prognostic significance of vascular endothelial growth factor protein in node-negative breast carcinoma. , 1997, Journal of the National Cancer Institute.
[20] Philippe Shubik,et al. VEGF and the quest for tumour angiogenesis factors , 2022 .